- Home
- REPL vs SLRC Comparison
REPL vs SLRC Comparison
Compare REPL & SLRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REPL
- SLRC
- Stock Information
- Founded
- REPL 2015
- SLRC 2007
- Country
- REPL United States
- SLRC United States
- Employees
- REPL 331
- SLRC N/A
- Industry
- REPL Biotechnology: Pharmaceutical Preparations
- SLRC Finance/Investors Services
- Sector
- REPL Health Care
- SLRC Finance
- Exchange
- REPL Nasdaq
- SLRC Nasdaq
- Market Cap
- REPL 1.1B
- SLRC 895.2M
- IPO Year
- REPL 2018
- SLRC 2010
- Fundamental
- Price
- REPL $13.98
- SLRC $17.65
- Analyst Decision
- REPL Strong Buy
- SLRC Sell
- Analyst Count
- REPL 6
- SLRC 4
- Target Price
- REPL $19.83
- SLRC $15.25
- AVG Volume (30 Days)
- REPL 610.9K
- SLRC 144.2K
- Earning Date
- REPL 02-12-2025
- SLRC 02-25-2025
- Dividend Yield
- REPL N/A
- SLRC 9.30%
- EPS Growth
- REPL N/A
- SLRC 34.99
- EPS
- REPL N/A
- SLRC 1.77
- Revenue
- REPL N/A
- SLRC $236,635,000.00
- Revenue This Year
- REPL N/A
- SLRC $4.11
- Revenue Next Year
- REPL $1,065.54
- SLRC N/A
- P/E Ratio
- REPL N/A
- SLRC $9.94
- Revenue Growth
- REPL N/A
- SLRC 5.79
- 52 Week Low
- REPL $4.92
- SLRC $14.41
- 52 Week High
- REPL $17.00
- SLRC $17.85
- Technical
- Relative Strength Index (RSI)
- REPL 55.54
- SLRC 72.27
- Support Level
- REPL $13.40
- SLRC $16.63
- Resistance Level
- REPL $14.59
- SLRC $17.85
- Average True Range (ATR)
- REPL 0.84
- SLRC 0.20
- MACD
- REPL -0.02
- SLRC 0.06
- Stochastic Oscillator
- REPL 66.52
- SLRC 83.61
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.
About SLRC SLR Investment Corp.
SLR Investment Corp is a closed-end externally managed, non-diversified management investment company that has elected to be treated as a business development company. It provides U.S. middle market businesses and intermediaries with bespoke debt financing solutions to fund working capital, acquisition, refinancing and growth capital requirements. It invests majorly in leveraged middle-market companies in the form of senior secured loans, financing leases and to a lesser extent, unsecured loans and equity securities.